Key Events This Week
29 Dec 2025: Stock opens at ₹1,424.15, declines 0.76%
30 Dec 2025: Technical momentum shifts to mildly bearish, stock falls 3.21%
31 Dec 2025: Stock surges 4.89% amid rating upgrade to Hold
1 Jan 2026: Technical momentum shifts to mildly bullish, stock closes at ₹1,445.90
2 Jan 2026: Momentum shifts sideways, stock declines 0.83%

Wockhardt Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-01-02 08:02:15Wockhardt Ltd has experienced a notable shift in its technical momentum as it transitions from a mildly bullish stance to a sideways trend, reflecting a complex interplay of technical indicators. Despite a recent downgrade in daily moving averages and a modest decline in share price, the stock’s weekly and monthly signals present a nuanced picture for investors navigating the Pharmaceuticals & Biotechnology sector.
Read full news article
Wockhardt Ltd Upgraded to Hold as Technicals Improve Amid Mixed Financial Signals
2026-01-01 08:03:58Wockhardt Ltd has seen its investment rating upgraded from Sell to Hold as of 31 Dec 2025, reflecting a notable improvement in its technical indicators and quarterly financial results. Despite lingering concerns over long-term fundamentals and valuation, the company’s recent operational performance and a shift in market sentiment have prompted a reassessment of its outlook.
Read full news article
Wockhardt Ltd Technical Momentum Shifts Signal Mildly Bullish Outlook
2026-01-01 08:01:19Wockhardt Ltd has exhibited a notable shift in its technical momentum as it transitions from a mildly bearish to a mildly bullish trend, reflecting improving investor sentiment in the Pharmaceuticals & Biotechnology sector. Key technical indicators such as MACD, Bollinger Bands, and On-Balance Volume (OBV) suggest a cautiously optimistic outlook, despite some mixed signals from moving averages and monthly trend assessments.
Read full news article
Wockhardt Ltd Technical Momentum Shifts Amid Mixed Market Signals
2025-12-30 08:03:37Wockhardt Ltd has experienced a notable shift in its technical momentum as December 2025 closes, with mixed signals emerging from key indicators such as MACD, RSI, and moving averages. Despite a recent downgrade in its Mojo Grade to Sell from Strong Sell, the stock’s price action and technical parameters reveal a complex picture for investors navigating the Pharmaceuticals & Biotechnology sector.
Read full news article









